SAR566658
Total Payments
$19,922
Transactions
20
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $750.00 | 1 | 0 |
| 2018 | $953.23 | 2 | 0 |
| 2017 | $18,219 | 17 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,580 | 4 | 73.2% |
| Unspecified | $4,162 | 11 | 20.9% |
| Travel and Lodging | $1,180 | 5 | 5.9% |
Payments by Type
General
$15,760
9 transactions
Research
$4,162
11 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | SANOFI US SERVICES INC. | $4,162 | 0 |
Ad
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $15,760
- SANOFI US SERVICES INC. $4,162
Product Information
- Type Drug
- Total Payments $19,922
- Total Doctors 3
- Transactions 20
About SAR566658
SAR566658 is a drug associated with $19,922 in payments to 3 healthcare providers, recorded across 20 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2017 to 2019. In 2019, $750.00 was paid across 1 transactions to 0 doctors.
The most common payment nature for SAR566658 is "Consulting Fee" ($14,580, 73.2% of total).
SAR566658 is associated with 1 research study, including "Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer" ($4,162).